title: Factors associated with changes in self-reported health status in infliximab-treated inflammatory bowel disease patients: results from a case management survey.
abstract: BACKGROUND
  Canadian inflammatory bowel disease patients treated with infliximab are predominantly managed through a nationwide case management system, named BioAdvance(®).
  
  
  METHODS
  A web-based survey was provided to patients currently receiving infliximab therapy within BioAdvance(®). Patients were categorized according to health trajectories: decliners, non-changers, moderate increasers and strong increasers. Factors associated with health trajectories were identified using multivariable multinomial logistic regression.
  
  
  RESULTS
  918 of 1160 respondents were inflammatory bowel disease patients reporting health status. Strong increasers were more likely to use educational tools than non-changers (adjusted odds ratio [aOR]: 1.65; 95% CI: 1.03-2.64), to be treated for ulcerative colitis (aOR: 2.05; 95% CI: 1.16-3.64) and to perceive case management as important (aOR: 2.52; 95% CI: 1.56-4.09). Younger (aOR: 0.72; 95% CI: 0.63-0.83) and French-speaking (aOR: 0.34; 95% CI: 0.18-0.63) patients were less likely to miss workdays. Patients were more likely to have missed workdays prior to joining the case management program.
  
  
  CONCLUSIONS
  Inflammatory bowel disease patients receiving infliximab within the nationwide case management system report a positive impact on health status and absenteeism.
authors.affiliation: School of Population and Public Health, University of British Columbia, Vancouver, Canada.
authors.forename: Steve
authors.initials: S
authors.lastname: Kanters
authors.forename: Kristian
authors.initials: K
authors.lastname: Thorlund
authors.forename: Kuhan
authors.initials: K
authors.lastname: Perampaladas
authors.forename: Peter
authors.initials: P
authors.lastname: Dyrda
authors.forename: Martin
authors.initials: M
authors.lastname: Williamson
authors.forename: Jennifer
authors.initials: J
authors.lastname: Jones
mesh_terms: D000041:Absenteeism; D000328:Adult; D000367:Age Factors; D002170:Canada; D019090:Case Management / Q000706:statistics & numerical data*; D003093:Colitis, Ulcerative / Q000145:classification / Q000188:drug therapy*; D003424:Crohn Disease / Q000145:classification / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D007802:Language; D008297:Male; D008875:Middle Aged; D010353:Patient Education as Topic / Q000706:statistics & numerical data; D017060:Patient Satisfaction; D012017:Referral and Consultation / Q000706:statistics & numerical data; D057566:Self Report; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D000069285:Infliximab
keywords: case management; inflammatory bowel disease; infliximab